Keywords: NSCLC, Lung cancer, Decision Resources, Lilly, Genentech, Roche, Alimta, Tarceva,

Non-small-cell lung cancer drug market to grow to over $6.5 billion in 2019

Article | 07 October 2010

Print This

Sales of non-small-cell lung cancer (NSCLC) drugs will increase from around $4 billion in 2009 to more than $6.5 billion in 2019 in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in